Published in AIDS Weekly, October 25th, 1999
"We are very excited about the prospects for Ampligen to fill a major void in our overall therapeutic approach to HIV. This excitement is based on our experience, not only with Ampligen, but other promising immunotherapeutics - regrettably of which...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.